# Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

> **NCT05116462** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 506 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Sintilimab
- **DRUG:** Cisplatin
- **DRUG:** Nab paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05116462
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-15
- **Primary completion:** 2026-09-30
- **Final completion:** 2028-10-14
- **Target enrollment:** 506 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116462, "Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05116462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*